Advancing use of long-acting and extended delivery HIV prevention and treatment regimens.
作者信息
Delany-Moretlwe Sinéad, Flexner Charles, Bauermeister José A
机构信息
Wits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South Africa.
Divisions of Clinical Pharmacology and Infectious Diseases, Johns Hopkins University, Baltimore, Maryland, USA.
出版信息
J Int AIDS Soc. 2023 Jul;26 Suppl 2(Suppl 2):e26126. doi: 10.1002/jia2.26126.
Abstract
摘要
相似文献
1
Advancing use of long-acting and extended delivery HIV prevention and treatment regimens.推进长效和缓释型艾滋病毒预防与治疗方案的应用。
J Int AIDS Soc. 2023 Jul;26 Suppl 2(Suppl 2):e26126. doi: 10.1002/jia2.26126.
2
Advancing long-acting and extended delivery HIV prevention and treatment regimens through behavioural science: NIH workshop directions.通过行为科学推进长效和延长给药的艾滋病毒预防与治疗方案：美国国立卫生研究院研讨会指南
AIDS. 2021 Jul 1;35(8):1313-1317. doi: 10.1097/QAD.0000000000002863.
3
The importance of the "how": the case for differentiated service delivery of long-acting and extended delivery regimens for HIV prevention and treatment.“怎么做”的重要性：针对艾滋病毒预防和治疗提供长效和延展药物方案的差异化服务交付的案例。
J Int AIDS Soc. 2023 Jul;26 Suppl 2(Suppl 2):e26095. doi: 10.1002/jia2.26095.
4
Long-Acting HIV Drugs for Treatment and Prevention.长效抗 HIV 药物：治疗与预防用途
Annu Rev Med. 2019 Jan 27;70:137-150. doi: 10.1146/annurev-med-041217-013717. Epub 2018 Oct 24.
5
Long-acting agents for HIV infection: biological aspects, role in treatment and prevention, and patient's perspective.用于治疗HIV感染的长效药物：生物学特性、在治疗和预防中的作用以及患者视角
New Microbiol. 2017 Apr;40(2):75-79. Epub 2017 Apr 3.
6
Advancing the use of Long-Acting Extended Delivery formulations for HIV prevention in sub-Saharan Africa: challenges, opportunities, and recommendations.推进长效延展型艾滋病预防药物在撒哈拉以南非洲的应用：挑战、机遇与建议。
J Int AIDS Soc. 2023 Jul;26 Suppl 2(Suppl 2):e26115. doi: 10.1002/jia2.26115.
7
Long-acting drugs and formulations for the treatment and prevention of HIV infection.长效药物和制剂，用于治疗和预防 HIV 感染。
Int J Antimicrob Agents. 2021 Jan;57(1):106220. doi: 10.1016/j.ijantimicag.2020.106220. Epub 2020 Nov 6.
8
Voluntary licensing of long-acting HIV prevention and treatment regimens: using a proven collaboration- and competition-based mechanism to rapidly expand at-scale, sustainable, quality-assured and affordable supplies in LMICs.长效 HIV 预防和治疗方案的自愿许可：利用成熟的合作和竞争机制，在中低收入国家迅速扩大大规模、可持续、有质量保证且负担得起的供应。
J Int AIDS Soc. 2023 Jul;26 Suppl 2(Suppl 2):e26092. doi: 10.1002/jia2.26092.
9
Considerations and challenges in developing novel long-acting antiretrovirals modalities for treatment and prevention of HIV-1 infection: a regulatory perspective.从监管角度看开发用于治疗和预防HIV-1感染的新型长效抗逆转录病毒药物的考量与挑战
Curr Opin HIV AIDS. 2020 Jan;15(1):61-65. doi: 10.1097/COH.0000000000000587.
10
Delivery of long-acting injectable antivirals: best approaches and recent advances.长效注射用抗病毒药物的给药：最佳方法与最新进展。
Curr Opin Infect Dis. 2015 Dec;28(6):603-10. doi: 10.1097/QCO.0000000000000214.
引用本文的文献
1
Preferences for Long-Acting HIV Pre-Exposure Prophylaxis among Women of Reproductive Age in Low- and Middle-income Countries: A Systematic Review.低收入和中等收入国家育龄妇女对长效艾滋病毒暴露前预防的偏好：一项系统评价
AIDS Behav. 2025 Jul 21. doi: 10.1007/s10461-025-04821-9.
2
Feasibility and acceptability of persons on long-acting cabotegravir for HIV prevention in the SEARCH Dynamic Choice HIV Prevention trial extension in rural Kenya and Uganda: a longitudinal cohort study.在肯尼亚农村和乌干达开展的SEARCH动态选择HIV预防试验扩展研究中，长效卡博特韦用于HIV预防的可行性及可接受性：一项纵向队列研究
J Int AIDS Soc. 2025 Jul;28 Suppl 2(Suppl 2):e26465. doi: 10.1002/jia2.26465.
3
Acceptability of long-acting antiretroviral therapy among people living with HIV who use drugs in Vancouver, Canada: A qualitative study.加拿大温哥华使用毒品的艾滋病毒感染者对长效抗逆转录病毒疗法的可接受性：一项定性研究。
PLoS One. 2025 Feb 28;20(2):e0319010. doi: 10.1371/journal.pone.0319010. eCollection 2025.
4
Current Challenges, Solutions, and Novel Directions in Research and Clinical Care: Proceedings From the 14th Annual International Workshop on HIV and Aging.研究与临床护理中的当前挑战、解决方案及新方向：第14届HIV与衰老年度国际研讨会会议论文集
J Gerontol A Biol Sci Med Sci. 2024 Dec 11;80(1). doi: 10.1093/gerona/glae259.
5
A conjoint experiment of three placebo rectal products used with receptive anal sex: results from MTN-035.一项与接受肛交同时使用的三种安慰剂直肠产品的联合试验：MTN-035 的结果。
J Int AIDS Soc. 2024 Mar;27(3):e26219. doi: 10.1002/jia2.26219.
本文引用的文献
1
Securing accelerated access to long-acting injectable cabotegravir for HIV prevention in low- and middle-income countries.确保在中低收入国家加速获得长效注射用卡替拉韦用于 HIV 预防。
J Int AIDS Soc. 2023 Jul;26 Suppl 2(Suppl 2):e26101. doi: 10.1002/jia2.26101.
2
Population-level impact of expanding PrEP coverage by offering long-acting injectable PrEP to MSM in three high-resource settings: a model comparison analysis.在三个资源丰富的地区为男男性行为者提供长效注射型 PrEP 以扩大 PrEP 覆盖面的人群影响：模型比较分析。
J Int AIDS Soc. 2023 Jul;26 Suppl 2(Suppl 2):e26109. doi: 10.1002/jia2.26109.
3
Voluntary licensing of long-acting HIV prevention and treatment regimens: using a proven collaboration- and competition-based mechanism to rapidly expand at-scale, sustainable, quality-assured and affordable supplies in LMICs.长效 HIV 预防和治疗方案的自愿许可：利用成熟的合作和竞争机制，在中低收入国家迅速扩大大规模、可持续、有质量保证且负担得起的供应。
J Int AIDS Soc. 2023 Jul;26 Suppl 2(Suppl 2):e26092. doi: 10.1002/jia2.26092.
4
Preparing for long-acting PrEP delivery: building on lessons from oral PrEP.准备长效 PrEP 给药：借鉴口服 PrEP 的经验。
J Int AIDS Soc. 2023 Jul;26 Suppl 2(Suppl 2):e26103. doi: 10.1002/jia2.26103.
5
The importance of the "how": the case for differentiated service delivery of long-acting and extended delivery regimens for HIV prevention and treatment.“怎么做”的重要性：针对艾滋病毒预防和治疗提供长效和延展药物方案的差异化服务交付的案例。
J Int AIDS Soc. 2023 Jul;26 Suppl 2(Suppl 2):e26095. doi: 10.1002/jia2.26095.
6
Benefits and limitations of different study designs for long-acting antiretroviral therapy among people living with HIV with viremia.不同研究设计对病毒血症HIV感染者长效抗逆转录病毒疗法的益处和局限性
J Int AIDS Soc. 2023 Jul;26 Suppl 2(Suppl 2):e26093. doi: 10.1002/jia2.26093.
7
Advancing the use of Long-Acting Extended Delivery formulations for HIV prevention in sub-Saharan Africa: challenges, opportunities, and recommendations.推进长效延展型艾滋病预防药物在撒哈拉以南非洲的应用：挑战、机遇与建议。
J Int AIDS Soc. 2023 Jul;26 Suppl 2(Suppl 2):e26115. doi: 10.1002/jia2.26115.
8
Including pregnant and breastfeeding people in trials of novel LAED PrEP agents: perspectives from sub-Saharan Africa community stakeholders.将孕妇和哺乳期妇女纳入新型长效暴露前预防药物试验：撒哈拉以南非洲社区利益相关者的观点
J Int AIDS Soc. 2023 Jul;26 Suppl 2(Suppl 2):e26120. doi: 10.1002/jia2.26120.
9
Implementation and resource needs for long-acting PrEP in low- and middle-income countries: a scoping review.中低收入国家长效预防用 PrEP 的实施和资源需求：范围综述。
J Int AIDS Soc. 2023 Jul;26 Suppl 2(Suppl 2):e26110. doi: 10.1002/jia2.26110.
10
What will it take for an injectable ARV to change the face of the HIV epidemic in high-prevalence countries? Considerations regarding drug costs and operations.注射用抗逆转录病毒药物如何改变高流行国家的 HIV 流行局面？关于药物成本和运营的考虑因素。
J Int AIDS Soc. 2023 Jul;26 Suppl 2(Suppl 2):e26106. doi: 10.1002/jia2.26106.
Zotero 插件